• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About
  • Gowling WLG
  • Legal information
  • Privacy statement
  • Cookie Policy
  • Home
  • About
  • Posts
  • Blogs
    • B2022
    • The IP Blog
    • Public Law & Regulation
    • AI
    • The Unified Patents Court

LoupedIn

Joining the fight against COVID-19 – One vaccine at a time

April 26, 2021, Patrick Duxbury

Joining the fight against COVID-19 – One vaccine at a time

It’s been just over a year since the start of the COVID-19 pandemic and national lockdowns were enforced in countries across the world. Nobody really knew what was happening or when we’d return to normal. Or if we’d ever return to normal.

12 months on and vaccination programs are progressing well in some countries, not so well in many others. As a result, restrictions are starting to lift in some countries with the hope that this will be the case on a global basis sooner rather than later. There is even a chance that something like normal life might return. Pub gardens and gyms have now opened in England and we will even be able to enjoy a meal in a restaurant with friends and family next month.

Our international Life Sciences team has played a crucial role in the global efforts to develop effective vaccines, advising on a trio of landmark COVID-19 projects. Our UK team has advised on the Pfizer/BioNTech vaccine, which was the first to be approved, while our Canadian team acted for Precision NanoSystems, Inc (PNI) on its agreement with Can Sino Biologics Inc. to co-develop an mRNA lipid nanoparticle (mRNA-LNP) vaccine.

We have also advised long standing client AstraZeneca on its landmark collaboration agreement for the development and commercialisation of the University of Oxford’s recombinant adenovirus COVID-19 vaccine (known as ChAdOx1 nCoV-19). The arrangement enabled the two organisations to globally develop, manufacture and distribute the University’s COVID-19 vaccine, which has now been approved in many countries and is a key part of the global vaccination program. I had my first shot of the AstraZeneca/Oxford vaccine a month ago. I couldn’t possibly have imagined that less than 10 months after assisting AZ on the transaction I would actually be a recipient of the vaccine!

As well as being a landmark deal for AstraZeneca, this has also been a huge achievement for our team. The sheer volume of work that had to be done in a very short timeframe was obviously a huge challenge, with many of us often wondering whether there were enough hours in the day to complete it. It was also one of the first deals we’d done completely remotely – everything was done via Zoom/Teams and we had to quickly adapt to this new way of working.

I am immensely proud of what our team has achieved. These will be the projects of a lifetime for many of us and I’m sure we will be celebrating properly as soon as we’re able to!

About the author(s)

Patrick Duxbury
View Patrick's profile |  See recent postsBlog biography

Patrick Duxbury helps clients to research, develop, manufacture and sell pharmaceutical, biotech and medical device products, using his extensive experience of structuring and executing transactions in the life sciences sector.

    This author does not have any more posts.

Patrick Duxbury

Patrick Duxbury helps clients to research, develop, manufacture and sell pharmaceutical, biotech and medical device products, using his extensive experience of structuring and executing transactions in the life sciences sector.

Filed Under: Uncategorized Tagged With: COVID-19, Intellectual Property, Life sciences

Views expressed in this blog do not necessarily reflect those of Gowling WLG.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Primary Sidebar

Recent Posts

  • Sole(ly) aesthetic? The Birkenstock Sandal goes to the Federal Court of Justice
  • UK Litigation Funding: reform or retain?
  • Arbitration Act 2025 receives Royal Assent

Tags

Artificial Intelligence (AI) (62) Autonomous vehicles (11) b2022 (19) Birmingham 2022 (8) Birmingham 2022 Commonwealth Games (15) Brexit (23) Climate change (16) Collective defined contribution (6) COP26 (11) Copyright (11) COVID-19 (23) Cyber security (7) Data protection (8) Defined contribution (7) Dispute Resolution (14) Employment (14) employment law (11) Environment (18) Environmental Societal Governance (9) ESG (50) ESG and pensions (11) General Election 2024 and pensions (8) Intellectual Property (86) IP (10) Life sciences (7) litigation funding (8) net zero (6) Patents (40) Pensions (53) Pension Schemes Act 2021 (11) Pensions dashboards (7) Pensions in 2022 (10) Pensions law (43) Procurement (7) Public Law & Regulation (39) Real Estate (27) Retail (8) sustainability (21) Tech (58) The Week In Pensions (11) Trademarks (16) UK (15) unified patents court (9) UPC (39) Week in HR (8)

Categories

Archives

Gowling WLG is an international law firm comprising the members of Gowling WLG International Limited, an English Company Limited by Guarantee, and their respective affiliates. Each member and affiliate is an autonomous and independent entity. Gowling WLG International Limited promotes, facilitates and co-ordinates the activities of its members but does not itself provide services to clients. Our structure is explained in more detail on our Legal Information page.

Footer

  • Home
  • About
  • Gowling WLG
  • Legal information
  • Privacy statement
  • Cookie Policy

© 2025 Gowling WLG